Regeneron and Sanofi Report Results of Libtayo (cemiplimab) in P-III Trial for Cervical Cancer

 Regeneron and Sanofi Report Results of Libtayo (cemiplimab) in P-III Trial for Cervical Cancer

Regeneron and Sanofi Report Results of Libtayo (cemiplimab) in P-III Trial for Cervical Cancer

Shots:

  • The P-III trial involves assessing Libtayo (300mg, IV, q3w) as monothx. vs CT in patients with recurrent or metastatic cervical cancer that has progressed on platinum-based CT. The trial enrolled patients regardless of their PD-L1 status
  • The results demonstrated a 31% reduction in the risk of death in the total population, improvement in OS, median survival (12.0 mos. vs 8.5mos). The trial will stop early, following the IDMC recommendation
  • Libtayo is a fully-human mAb targeting the immune checkpoint receptor PD-1 on T-cells. Both the companies plan the regulatory submission of the therapy in 2021

Click here ­to­ read full press release/ article | Ref: Regeneron | Image: Livable Limerick

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post